<DOC>
	<DOCNO>NCT00023816</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness carbendazim treat patient advance solid tumor lymphoma .</brief_summary>
	<brief_title>Carbendazim Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose carbendazim patient advance solid tumor lymphoma . II . Determine qualitative quantitative toxic effect drug patient . III . Determine pharmacokinetics drug patient . IV . Determine recommend phase II dose drug . V. Determine antitumor effect drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive oral carbendazim 2-3 time daily 5 day week 3-4 week . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carbendazim maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 30 day . PROJECTED ACCRUAL : Approximately 30-60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carbendazim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor standard therapy exists progress recurred prior therapy OR Lymphoma therapeutic option exist No hematological malignancy ( e.g. , leukemia ) No know brain leptomeningeal disease unless previously treat radiotherapy , currently treat corticosteroid therapy , clinical symptom present PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,000/mm3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL AST ALT great 3 time upper limit normal ( ULN ) ( 5 time ULN due tumor involvement ) Alkaline phosphatase less 2.5 time ULN Renal : Creatinine great 2 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No unstable atrial ventricular arrhythmia require control medication No ischemic event within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Abnormalities would affect absorption study drug allow investigator 's discretion No severe disease psychiatric disorder would preclude study No phenylketonuria No know hypersensitivity reaction artificial sweetener aspartame ( e.g. , Nutrasweet ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Recovered prior chemotherapy cancer No concurrent cytotoxic therapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Recovered prior radiotherapy cancer Surgery : Recovered prior surgery cancer Prior gastrointestinal surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>